An engineered live biotherapeutic protects the intestinal microbiome against unwanted consequences of antibiotic therapies and could be developed as a simple and effective co-therapy
By Benjamin Boettner
(BOSTON) – Many of us have experienced our gut thrown off-balance as a result of an unavoidable antibiotic therapy. Antibiotics not only kill the pathogenic bacteria causing an infection, they also indiscriminately wreak havoc on the trillions of “good” bacteria making up the human microbiota. Known as “dysbiosis,” this alteration of our gut microbial composition triggers discomforting diarrhea in up to 35% of patients in the short term, and can take months to resolve, often with the help of dietary corrections and supplements. In some patients, the microbiota can even be permanently disturbed, which becomes a serious risk factor for a host of autoimmune, metabolic, and neurological diseases.
This is because we have evolved a mutually highly beneficial relationship with the microbes in our gut microbiome and in fact formed a “superorganism” with them in which we as “hosts” shape our microbiome’s composition with our gut environment, as well as our eating and other habits. In turn, our microbial “guests” produce diverse compounds that profoundly affect the way we digest food, utilize energy, and support our immunity, among many other functions. Despite the importance of our microbiome for our health, thus far there has been no silver bullet to prevent antibiotic-induced dysbiosis.
Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Massachusetts Institute of Technology (MIT), using a synthetic biology approach, has developed an engineered live biotherapeutic product (eLBP) that, when given together with commonly used antibiotics known as β-lactams (which includes the well-known antibiotic penicillin), protects the gut microbiome from dysbiosis. The study is published in Nature Biomedical Engineering.
“In designing the eLBP, we tapped into the synthetic biology took kit that we have advanced over the past two decades and enabled Lactococcus lactis, a safe-to-use microbe, to secrete a β-lactamase enzyme that altruistically degrades β-lactams in the bacteria’s environment,” said Wyss Core Faculty member and lead of the Institute’s Living Cellular Device Platform, James Collins, Ph.D., who led the study. “The enzyme essentially becomes a ‘common good’ that cannot confer a selective advantage to the producing bacteria or be easily transferred to other bacteria, minimizing the risk and maximizing the clinical benefits of our approach.” Collins is also the Termeer Professor of Medical Engineering & Science at MIT. In 2018, his team used L. lactis to develop an engineered probiotic intervention to detect and treat cholera infections.
Protection from antibiotics goes live
Usually, β-lactamase enzymes are encoded by a single gene that can be passed between bacteria via a process called horizontal gene transfer, and the enzymes themselves reside within the bacteria’s cell wall or membrane enclosures. This not only makes the producing bacterial strain resistant to certain antibiotics that attack these outer enclosures, but also allows their resistance to spread to other bacteria in the gut microbial population. “To safeguard against the development and spread of antibiotic resistance, we engineered various control units into the β-lactamase expression system. Essentially, we split a specific β-lactamase-encoding gene, distributed the two genetically unlinked halves to different parts of the bacterium’s DNA, and further engineered them so that they would be secreted away from the producer cell and bind to each other with high affinity to reassemble a functional enzyme in its outside environment,” said first-author Andrés Cubillos-Ruiz, Ph.D., who spearheaded the project in Collins’ group.
Cubillos-Ruiz and his co-workers on Collins’ team then showed that when they gave their eLBP intervention to mice that received the antibiotic ampicillin as an oral treatment, it indeed minimized dysbiosis in each animal’s gut. By sequencing a part of the bacterial genome known as 16S rDNA, which provides a genetic zip code for all bacterial species and families, they found that the eLBP significantly dampened the collapse of microbial populations and allowed them to fully recover their original diversity and composition three days after antibiotic treatment. Mice treated with ampicillin that were not protected by the eLPB, suffered a much greater loss of their microbial diversity which they could not recover during the entire course of the experiment.
“Importantly, during its transient stay in the digestive tract, the eLBP protected the microbiome without changing the concentration of ampicillin circulating in the blood, which is important because the antibiotic still needs to reach infections everywhere else in the body to do its job,” said Cubillos-Ruiz. “The eLBP also reduced the enrichment of various antibiotic resistance genes within the microbial community, which commonly happens under the selective pressure of antibiotics.” The gut microbiome contains a natural pool of bacteria with genes, including β-lactamase genes, that induce resistance to antibiotics through different mechanisms – including resistance even to unrelated antibiotics. With every antibiotic treatment their numbers shoot up and also contribute to the spread of antibiotic resistance by horizontal gene transfer.
Keeping a lid on opportunistic bacteria
Finally, the team addressed a common consequence of dysbiosis: the hostile takeover of the vacated intestinal territory by problematic bacteria like Clostridioides difficile. These “opportunistic bacteria” live in many people’s intestines at lower numbers and, when given the chance to multiply uncontrollably, trigger inflammation, diarrhea, and may contribute to the development of inflammatory bowel disease. The team modeled a full-fledged human C. difficile infection by infecting ampicillin-treated mice with spores of C. difficile. The eLBP successfully prevented the intestinal colonization with C. difficile, in contrast to a normal unmodified L. lactis strain not producing the split β-lactamase enzyme.
“This is one of the strongest examples of an engineered living cellular therapy tackling a pressing clinical problem coming out of academia thus far,” said Collins.
“We are now focusing on getting these living therapies to patients and are finalizing the design of an effective, short, and inexpensive clinical trial,”said Cubillos-Ruiz, adding that, “We also believe that our general eLBP approach can be extended into a therapeutic platform that could be applied not only to other antibiotics, but also to address diseases where gut dysbiosis is at the center.”
This elegantly engineered and highly effective living cellular therapeutic device could become a true game changer in the treatment of infectious diseases both by helping to maintain a healthy microbiome in patients treated with antibiotics and, perhaps equally important in the longer run, by preventing the growing problem of antibiotic resistance which is a growing problem worldwide,” said Wyss Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at HMS and Boston Children’s Hospital, and the Hansjörg Wyss Professor of Bioinspired Engineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.
Other authors on the study are Miguel Alcantar and Nina Donghia from Collins’ group, Pablo Cárdenas from the MIT Department of Biological Engineering, and Julian Avila-Pacheco from the Broad Institute. The study was funded by the Wyss Institute at Harvard University, a Defense Threat Reduction Agency grant (#HDTRA1-14-1-0006), and the Paul G. Allen Frontiers Group.